Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is a clinical-stage biotechnology company developing therapies in oncology and obesity. Its pipeline includes CRB-701, a Nectin-4-targeting antibody-drug conjugate being studied in advanced solid tumors, and CRB-913, an oral, peripherally restricted CB1 receptor… From the company’s description.
In fiscal 2025, Corbus Pharmaceuticals Holdings, Inc. reported a net loss of $78.54M. Operations used $64.49M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Corbus Pharmaceuticals Holdings, Inc. does
In the company’s own words
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is a clinical-stage biotechnology company developing therapies in oncology and obesity. Its pipeline includes CRB-701, a Nectin-4-targeting antibody-drug conjugate being studied in advanced solid tumors, and CRB-913, an oral, peripherally restricted CB1 receptor inverse agonist being developed for obesity. The company also has CRB-601, an anti-αvβ8 antibody program that it has deprioritized. Corbus licenses CRB-701 from CSPC for development and commercialization in the United States, Canada, Europe, the United Kingdom and Australia, and holds a worldwide license for CRB-913. It conducts clinical development and relies on contract manufacturers and licensing partners for drug supply; it does not report operating segments. The company’s Phase 1/2 CRB-701 study and Phase 1b CRB-913 study are underway. Research and development expenses were $70.1 million for the year ended December 31, 2025. Its website is www.corbuspharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NORWOOD, MA
- Fiscal year end
- December
- CIK
- 1595097
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Corbus Pharmaceuticals Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Corbus Pharmaceuticals Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Corbus Pharmaceuticals Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Corbus Pharmaceuticals Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Corbus Pharmaceuticals Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”